USANA Health Sciences (NYSE:USNA) Cut to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen downgraded USANA Health Sciences to “Hold” from “Buy,” while other analysts have also lowered their views; the stock’s overall consensus rating is “Reduce.”
• USANA’s latest quarterly results missed expectations, with an adjusted loss of $0.07 per share versus estimates for earnings of $0.43 and revenue of $223.27 million versus $235 million expected.
• Shares opened at $15.43, near their 12-month low of $14.35, while insiders have sold $261,441 worth of stock over the past 90 days; institutional investors own 54.25% of the company.

USANA Health Sciences (NYSE:USNA - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Saturday.

A number of other research analysts have also recently issued reports on the stock. Zacks Research cut shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 22nd. Weiss Ratings restated a "sell (d)" rating on shares of USANA Health Sciences in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Reduce".

USANA Health Sciences Stock Up 3.6%

Shares of USANA Health Sciences stock opened at $15.43 on Friday. USANA Health Sciences has a twelve month low of $14.35 and a twelve month high of $32.32. The company has a 50-day simple moving average of $20.41 and a two-hundred day simple moving average of $19.66. The stock has a market capitalization of $284.84 million, a price-to-earnings ratio of -12.75, a price-to-earnings-growth ratio of 1.63 and a beta of 0.73.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.43 by ($0.50). The business had revenue of $223.27 million for the quarter, compared to analyst estimates of $235.00 million. USANA Health Sciences had a positive return on equity of 3.41% and a negative net margin of 2.43%.USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. On average, sell-side analysts anticipate that USANA Health Sciences will post 0.76 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Brent Neidig sold 5,002 shares of the business's stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $19.45, for a total value of $97,288.90. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director John Turman Fleming sold 2,450 shares of the company's stock in a transaction on Monday, June 1st. The shares were sold at an average price of $17.93, for a total transaction of $43,928.50. Following the sale, the director directly owned 4,230 shares in the company, valued at $75,843.90. This trade represents a 36.68% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 13,869 shares of company stock valued at $261,441 over the last 90 days. 0.82% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Pzena Investment Management LLC bought a new stake in shares of USANA Health Sciences during the 2nd quarter valued at about $25,739,000. BlackRock Inc. acquired a new stake in USANA Health Sciences during the second quarter worth approximately $33,182,000. Deutsche Bank AG bought a new stake in USANA Health Sciences in the second quarter worth approximately $822,000. Bank of New York Mellon Corp bought a new stake in USANA Health Sciences in the second quarter worth approximately $1,105,000. Finally, State of Wyoming bought a new stake in USANA Health Sciences in the second quarter worth approximately $242,000. 54.25% of the stock is owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company's portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA's products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source